Veterinary Medicines

Vanguard Plus 7, süstelahuse lüofilisaat ja lahusti koertele

Authorised
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain N-CDV, Live
Download as PDF

Product identification

Medicine name:
Vanguard Plus 7, süstelahuse lüofilisaat ja lahusti koertele
Active substance:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain N-CDV, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    40.00
    Hamster protective Dose 80 % (Ph. Eur. Monograph)
    /
    1.00
    dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    40.00
    Hamster protective Dose 80 % (Ph. Eur. Monograph)
    /
    1.00
    dose
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    cell culture infective dose 50
    /
    1.00
    dose
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    1000000.00
    cell culture infective dose 50
    /
    1.00
    dose
  • Canine adenovirus 2, strain Manhattan, Live
    1585.00
    cell culture infective dose 50
    /
    1.00
    dose
  • Canine distemper virus, strain N-CDV, Live
    1000.00
    cell culture infective dose 50
    /
    1.00
    dose
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1254
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 16/02/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."